Carboxyamidotriazole
Names
Preferred IUPAC name
5-Amino-1-{[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl}-1H -1,2,3-triazole-4-carboxamide
Identifiers
ChemSpider
ECHA InfoCard
100.231.281
EC Number
UNII
InChI=1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27)
N Key: WNRZHQBJSXRYJK-UHFFFAOYSA-N
N InChI=1/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27)
Key: WNRZHQBJSXRYJK-UHFFFAOYAY
C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2Cl)CN3C(=C(N=N3)C(=O)N)N)Cl)Cl
Properties
C17 H12 Cl3 N5 O2
Molar mass
424.66848
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
Chemical compound
Carboxyamidotriazole is a calcium channel blocker that blocks voltage-gated and ligand-gated calcium channels and has been investigated as an anti-cancer drug in vitro .[ 1] [ 2]
^ Figg, W. D.; Cole, K. A.; Reed, E.; Steinberg, S. M.; Piscitelli, S. C.; Davis, P. A.; Soltis, M. J.; Jacob, J.; Boudoulas, S.; Goldspiel, B. (1995). "Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction". Clinical Cancer Research . 1 (8): 797–803. PMID 9816048 .
^ Bonnefond, M. L.; Florent, R.; Lenoir, S.; Lambert, B.; Abeilard, E.; Giffard, F.; Louis, M. H.; Elie, N.; Briand, M.; Vivien, D.; Poulain, L.; Gauduchon, P.; n'Diaye, M. (2018). "Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BCLXL strategies through MCL-1 down-regulation" . Oncotarget . 9 (74): 33896–33911. doi :10.18632/oncotarget.26084 . PMC 6188062 . PMID 30338034 .